As in other cancer types [15, 32], MALAT1 was found to interact with the methyltransferase EZH2 also in MM cells, and both MALAT1 and EZH2 inhibitors reduced H3K27Me3 at KEAP1 promoter, thus upregulating KEAP1 mRNA. This evidence concerns the gene KEAP1 and Miyoshi myopathy.